MiniMed (MMED) CEO receives new RSU and stock option grants

Rhea-AI Filing Summary

MiniMed Group, Inc. Chief Executive Officer Dallara Que reported awards of new equity-based compensation. On March 9, 2026, Que received 83,334 performance-based restricted stock units, each representing a contingent right to one share of MiniMed common stock. These units vest on March 9, 2027 if MiniMed’s common stock closes at or above $32.05 per share as of the defined Divestment Date.

On the same date, Que also received 252,526 employee stock options with an exercise price of $18.00 per share and expiration on March 9, 2036. These options vest in tranches of 33% on each of March 9, 2028 and March 9, 2029, and 34% on March 9, 2030, providing a long-term incentive structure tied to future service and share price performance.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Dallara Que

Role Chief Executive Officer

Type	Security	Shares	Price	Value
Grant/Award	Performance-Based Restricted Stock Units	83,334	$0.00	--
Grant/Award	Employee Stock Option (Right to Buy)	252,526	$0.00	--

Holdings After Transaction: Performance-Based Restricted Stock Units — 83,334 shares (Direct); Employee Stock Option (Right to Buy) — 252,526 shares (Direct)

Footnotes (1)

1. Each performance-based restricted stock unit represents a contingent right to receive one share of MMED common stock. The performance-based restricted stock units vest on March 9, 2027, subject to MMED common stock achieving a closing price per share of at least $32.05 as of the Divestment Date (as defined in the Separation Agreement, dated March 1, 2026, by and between Medtronic Group Holding, Inc. and Kangaroo US Holdco 2, Inc.). The later of March 9, 2027 or the Divestment Date. The option vests 33% on each of March 9, 2028 and March 9, 2029, and 34% on March 9, 2030.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Dallara Que

(Last) (First) (Middle)

C/O 18000 DEVONSHIRE STREET

(Street)

NORTHRIDGE CA 91325

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
MiniMed Group, Inc. [ MMED ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/09/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Performance-Based Restricted Stock Units	(1)	03/09/2026		A		83,334		(1)	(2)	Common Stock	83,334	$0	83,334	D
Employee Stock Option (Right to Buy)	$18	03/09/2026		A		252,526		(3)	03/09/2036	Common Stock	252,526	$0	252,526	D

Explanation of Responses:

1. Each performance-based restricted stock unit represents a contingent right to receive one share of MMED common stock. The performance-based restricted stock units vest on March 9, 2027, subject to MMED common stock achieving a closing price per share of at least $32.05 as of the Divestment Date (as defined in the Separation Agreement, dated March 1, 2026, by and between Medtronic Group Holding, Inc. and Kangaroo US Holdco 2, Inc.).

2. The later of March 9, 2027 or the Divestment Date.

3. The option vests 33% on each of March 9, 2028 and March 9, 2029, and 34% on March 9, 2030.

Remarks:

	/s/ Bryan F. Kelly, attorney-in-fact	03/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did MiniMed (MMED) CEO Dallara Que report in this Form 4?

MiniMed CEO Dallara Que reported receiving equity compensation, not buying or selling shares in the market. The filing shows grants of performance-based restricted stock units and stock options that may convert into common stock if vesting and performance conditions are met.

How many RSUs and stock options were granted to the MiniMed (MMED) CEO?

Dallara Que received 83,334 performance-based restricted stock units and 252,526 employee stock options. Each RSU represents a right to one MiniMed common share, while each option allows purchase of one share at a preset exercise price if vesting conditions are satisfied.

What are the vesting conditions for Dallara Que’s MiniMed (MMED) performance-based RSUs?

The 83,334 performance-based RSUs vest on March 9, 2027 if MiniMed’s common stock achieves a closing price of at least $32.05 per share as of the Divestment Date defined in a March 1, 2026 Separation Agreement referenced in the filing footnotes.

What are the key terms of the MiniMed (MMED) stock options granted to the CEO?

The 252,526 stock options have a $18.00 exercise price and expire on March 9, 2036. They vest 33% on March 9, 2028, 33% on March 9, 2029, and 34% on March 9, 2030, aligning incentives with long-term company performance.

Does this MiniMed (MMED) Form 4 show the CEO buying or selling shares on the market?

No, the Form 4 shows grant/award acquisitions of RSUs and stock options, coded as “A.” These are compensation-related awards from the company, not open-market purchases or sales, and therefore do not reflect discretionary trading activity in MiniMed shares by the CEO.

How could the MiniMed (MMED) RSU performance condition affect the CEO’s compensation?

The 83,334 performance-based RSUs vest only if MiniMed’s stock closes at or above $32.05 per share as of the Divestment Date. If this price target is not reached, the RSUs may not convert into common shares, directly linking this portion of compensation to stock performance.